Telemus Capital LLC Purchases 252 Shares of Danaher Co. (NYSE:DHR)

Telemus Capital LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 2.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,628 shares of the conglomerate’s stock after purchasing an additional 252 shares during the period. Telemus Capital LLC’s holdings in Danaher were worth $2,311,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC grew its holdings in shares of Danaher by 96,490.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after purchasing an additional 23,262,904 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Danaher by 1.0% in the first quarter. Geode Capital Management LLC now owns 12,900,685 shares of the conglomerate’s stock valued at $3,243,696,000 after acquiring an additional 126,062 shares during the last quarter. Norges Bank bought a new stake in Danaher in the fourth quarter valued at approximately $2,057,164,000. Bank of New York Mellon Corp boosted its holdings in Danaher by 12.3% in the first quarter. Bank of New York Mellon Corp now owns 7,440,410 shares of the conglomerate’s stock valued at $1,875,281,000 after acquiring an additional 812,475 shares during the last quarter. Finally, Amundi boosted its holdings in Danaher by 8.4% in the fourth quarter. Amundi now owns 4,852,751 shares of the conglomerate’s stock valued at $1,321,312,000 after acquiring an additional 375,805 shares during the last quarter. 76.71% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of the stock in a transaction on Monday, August 21st. The stock was sold at an average price of $250.54, for a total transaction of $147,818.60. Following the completion of the transaction, the senior vice president now owns 6,939 shares in the company, valued at approximately $1,738,497.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of the stock in a transaction on Monday, August 21st. The stock was sold at an average price of $250.54, for a total transaction of $147,818.60. Following the completion of the transaction, the senior vice president now owns 6,939 shares in the company, valued at approximately $1,738,497.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Teri List sold 3,490 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $263.30, for a total value of $918,917.00. Following the completion of the transaction, the director now owns 17,494 shares of the company’s stock, valued at approximately $4,606,170.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,922 shares of company stock worth $12,552,233. 11.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently commented on DHR. Bank of America upped their target price on Danaher from $250.00 to $280.00 in a report on Wednesday, July 26th. Royal Bank of Canada increased their price target on Danaher from $260.00 to $292.00 in a report on Wednesday, July 26th. Raymond James increased their price target on Danaher from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Wednesday, July 26th. Stifel Nicolaus lowered their target price on Danaher from $250.00 to $240.00 and set a “hold” rating on the stock in a research report on Wednesday, July 26th. Finally, Barclays upped their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 25th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $289.79.

Danaher Stock Performance

Shares of Danaher stock traded up $1.77 during trading hours on Friday, hitting $255.25. 5,696,631 shares of the company’s stock traded hands, compared to its average volume of 2,877,042. Danaher Co. has a 12-month low of $221.22 and a 12-month high of $283.63. The stock has a market capitalization of $188.46 billion, a price-to-earnings ratio of 29.96, a PEG ratio of 2.72 and a beta of 0.80. The company has a fifty day simple moving average of $252.96 and a 200-day simple moving average of $245.06. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.08 and a quick ratio of 1.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 25th. The conglomerate reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.04. Danaher had a return on equity of 15.03% and a net margin of 20.95%. The firm had revenue of $7.16 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same period last year, the firm posted $2.76 EPS. The business’s revenue was down 7.7% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 8.84 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Thursday, October 12th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, October 11th. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. Danaher’s payout ratio is 12.68%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.